FDA Clearance Tracker · P930014-S161
AcrySof Single-Piece IOL (SA60AT); AcrySof IQ Aspheric IOL (SN60WF); AcrySof Aspheric UV-Absorbing IOL (SA60WF); AcrySof
Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Apr 30, 2026
Approved
Time to decision
90 days
Received Jan 30, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P930014-S161
- Device name
- AcrySof Single-Piece IOL (SA60AT); AcrySof IQ Aspheric IOL (SN60WF); AcrySof Aspheric UV-Absorbing IOL (SA60WF); AcrySof
- Applicant
- Alcon Laboratories, Inc.
- Applicant location
- Fort Worth, TX
- Received
- Jan 30, 2026
- Decided
- Apr 30, 2026
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P930014
Device type
- Device type
- intraocular lens (HQL)
- Device class
- Class III
- Regulation
- 21 CFR 886.3600
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
approval application (PMA) 180-day supplement, which requested approval for a new packaging configuration, automation of the primary and secondary packaging processes, and updates to shelf-life and storage conditions of the AcrySof IOLs (storage condition temperatures from 45 °C to 30 °C), and Clareon IOLs (to extend the shelf life from four (4) years to five (5) years at the temperature of 30 °C) in Alcons manufacturing facilities in West Virginia, USA and Cork, Ireland.
Source documents
Other decisions for Alcon Laboratories, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K254052 · Decided Feb 13, 2026 · 58 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.